I got INCY from a technical news article a long time ago. I got some other goodies from a smart broker who saw the kind of story I liked and kept an eye open.
Interesting prospect: MYRX. Spun out of MYGN with too much value in cash, so they're trying to turn it into income production in a way that'll help their business long-term (by buying JAV). The interesting part is a cancer drug candidate that concentrates in brain (most drugs are excluded from brain); going into late trials against melanoma and glioblastoma. As with INCY's JAK drugs, the potential off-label market dwarfs the on-label one.